37 results about "Progression-free survival" patented technology

The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and / or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

The invention discloses a risk score prediction curve of objective remission rate (ORR), disease control rate (DCR), progression-free lifetime (PFS) and total lifetime (OS) of a patient with advanced gastric or gastroesophageal junction adenocarcinoma after first-line chemotherapy and immunotherapy based on clinical inflammation indexes and application of the risk score prediction curve. The risk score is established based on clinical inflammation indexes and used for drawing a prediction curve of PFS and OS after first-line chemotherapy and immunotherapy and ORR and DCR, common inflammation-related laboratory indexes are integrated, the calculation method is simple, and clinical doctors and patients can conveniently operate to predict ORR, DCR, PFS and OS after treatment. Meanwhile, the risk score prediction model can provide certain help for selection of treatment schemes of later gastric or gastroesophageal junction adenocarcinoma patients in the future.

The present disclosure provides methods for improving the median progression-free lifetime (PFS) and improving the overall lifetime of a never-treated subject or a population of never-treated subjects having EGFR-positive non-small cell lung cancer (NSCLC).

Disclosed herein are compositions and methods for treating cancer, specifically extensive-stage small-cell lung cancer (ES-SCLC), through the administration of a combination therapy. In some embodiments, the method comprises administering plinabulin, one or more immune checkpoint inhibitors, including but not limited to pembrolizumab, and a regimen of etoposide with a platinum-based agent (EP). The disclosed methods enhance tumor reduction, prolong progression-free survival, and improve overall treatment efficacy compared to traditional therapies.

The invention discloses a prognosis marker and a dynamic prognosis prediction method for colorectal cancer liver metastasis. The method comprises the following steps: S1, acquiring clinical pathological characteristic data of a patient with colorectal cancer liver metastasis and a longitudinal laboratory marker measured during post-operation follow-up visit; s2, extracting a change trend of the longitudinal laboratory marker by utilizing multivariable function principal component analysis to obtain a principal component score; s3, training a random survival forest model by using the principal component score and the clinical pathological feature data to obtain a dynamic prediction model; s4, dynamically updating the score of the principal component based on a newly collected laboratory marker of postoperative follow-up visit of the patient, and outputting dynamic risk assessment results of the progression-free lifetime and the total lifetime of the patient through a dynamic prediction model; according to the method, the prediction model capable of dynamically evaluating the survival risk of the patient is constructed and updated by fusing the dynamic longitudinal laboratory marker and the static clinical pathological characteristics.

The invention discloses an infant AML prognosis model constructed by integrating transcriptomics and machine learning and a construction method of the infant AML prognosis model. The method comprises the following steps: collecting clinical data and whole genome transcriptome data of an infant AML patient; identifying difference up-regulation expression genes of infant AML relative to healthy control and old children AML in the discovery set, and screening intersection genes of the genes and an external verification set; carrying out model construction on the obtained gene by taking the progression-free lifetime of the patient as an outcome, generating a plurality of algorithm combinations based on a machine learning algorithm, and calculating a C-index index of each combination; determining a model with the highest C-index mean value in the internal verification set and the external verification set as an optimal model, calculating a risk score IPScore of each patient by using the model, and performing evaluation in the verification set; and dividing the patients into a low-risk group and a high-risk group according to IPScore by utilizing the optimal cutoff value 0.42, namely an IPGroup model. The model can accurately and effectively predict the prognosis of the infant AML patient, and has good clinical practicability.

Described herein are methods and compositions related to using genomic and / or methylation-based TF from a genomic, epigenomic detection platform to predict clinical benefit to therapies, including through evaluation of real-world patients. Tumor detection, methylation-based tumor fraction, and methylation-based molecular response are prognostic and predictive of outcomes, Prolonged treatment of patients not deriving benefit risks increased toxicity, may reduce chance of success for targeted treatments, and may increase clonal hematopoietic burden, wherein methylation based detection largely eliminates noise in determining genomic molecular response (gMR), thereby demonstrating advantageous use of methylation based molecular response (mMR).

The invention discloses a tumor main clone allele frequency dynamic monitoring and closed-loop control method, and belongs to the field of biological gene detection and data processing. The method comprises the following steps: firstly, constructing a state space dynamic model containing state parameters of a master clone and a slave clone, introducing a molecular regulatory factor, then setting a main clone allele frequency monitoring threshold interval, synchronously acquiring abundance of the master clone and the slave clone detected by digital PCR at multiple rates, CRP, albumin and other hematopathology indexes as observation parameters, and carrying out quantitative analysis on the observation parameters. According to the method, observation parameters are predicted based on an extended Kalman filtering fusion model, the main clone allele frequency is accurately estimated in real time, and according to a comparison result of the main clone allele frequency and a monitoring threshold interval, the number of days for taking or stopping the targeted drug is dynamically adjusted, so that closed-loop control of the main clone allele frequency is realized. Closed-loop fusion of tumor monitoring and drug administration regulation is achieved, drug resistance germination is intervened in advance, and the progression-free lifetime of a patient is remarkably prolonged.

To provide uses of pertuzumab, which is a first in-class HER2 dimerization inhibitors, and articles of manufacture comprising the same.SOLUTION: A method for extending progression free survival in a population of HER2 + breast carcinoma patients; a method for combining two HER2 antibodies to treat HER2 + breast carcinoma without increasing cardiotoxicity; a method for treating early HER2 + breast carcinoma; a method for treating HER2 + breast carcinoma by co-administering a mixture of pertuzumab and trastuzumab from the same I. v. bag; a method for treating HER2 + metastatic gastric carcinoma; a method for treating HER2 + breast carcinoma with pertuzumab, trastuzumab and vinorelbine; Methods for treating HER2 positive breast cancers with trastuzumab and aromatase inhibitors; and methods for treating low HER3 ovarian, primary peritoneal, or fallopian tube cancers are provided.SELECTED DRAWING: None

Disclosed are means for predicting (i) multi-organ metastasis and / or multifocal metastatic disease, and (ii) overall survival (OS) and progression-free survival (PFS) of subjects suffering from cancer, the predictions being based on the number and size of circulating cancer-associated macrophage-like cells (CAML) found in a biological sample, such as the blood, of the subject.

This disclosure provides a method for improving median progression-free survival (PFS) and overall survival in treatment-naive subjects or a treatment-naive population with EGFR-positive non-small cell lung cancer (NSCLC).

The present disclosure relates to methods of treating breast cancer in a patient, comprising administering to the patient a therapeutic combination comprising elacestrant, or a pharmaceutically acceptable salt thereof, and abemaciclib, or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating breast cancer in a patient that produce a longer Progression Free Survival time as compared to other treatments.

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has significantly prolonged progression-free survival (PFS) in EGFR-mutant lung cancer patients, including those with brain metastases. However, osimertinib-treated patients often develop lethal metastatic relapse, often to the brain. The genetic repression of S100A9, ALDH1A1, or RA receptors (RAR) in cancer cells, or treatment with a pan-RAR antagonist, dramatically reduces brain metastasis. S100A9 expression in cancer cells correlates with poor PFS in osimertinib-treated patients, and is identified as a novel, therapeutically targetable S100A9-ALDH1A1-RA axis. A combination of osimertinib and AGN-194310, for example, treats such cancer while avoiding metastatic relapse.

This invention relates to the pharmaceutical field, and more specifically to a drug used for the treatment of locally advanced, unresectable or metastatic colorectal cancer, and its use. Compared to a two-drug regimen of cintirimab + tucidinostat, the tripartite regimen of cintirimab + tucidinostat + IBI305 provided by this invention can significantly extend progression-free survival in patients with MSS / MSI-L locally advanced, unresectable or metastatic colorectal cancer. Furthermore, in terms of indicators such as ORR, PR, PD, NE, and DCR, patients with MSS / MSI-L locally advanced, unresectable or metastatic colorectal cancer can obtain significant benefits from the tripartite regimen of cintirimab + tucidinostat + IBI305.

The application relates to the field of medical technology, in particular to application of PTPRT as a biomarker and target point for predicting the curative effect of lung cancer immunological checkpoint treatment. The application provides application of the expression amount of PTPRT in curative effect prediction or evaluation of immunological checkpoint treatment of cancer. The experiment of the application shows that low expression of PTPRT can accurately predict the progression-free survival (PFS) of lung cancer patients after receiving immunological checkpoint treatment as a marker for predicting the curative effect of lung cancer immunological checkpoint treatment. Inhibition of PTPRT can increase the proportion of CD8+ T cells infiltrating tumors, and synergistically enhances the anti-tumor effect of an immunological checkpoint inhibitor.

This invention relates to the field of biomedical technology, providing the application of ACAT1 in the preparation of diagnostic and prognostic products for non-small cell lung cancer (NSCLC). Compared to existing technologies, the ACAT1 expressed in this invention is decreased in tumor tissues, and this decreased ACAT1 expression is associated with overall survival (OS) and progression-free survival (PFS), indicating a poor prognosis. Therefore, ACAT1 can serve as a biomarker for the diagnosis and prognostic prediction of NSCLC, inhibiting NSCLC cell proliferation and migration. Furthermore, as a key enzyme in β-oxidation, ACAT1 promotes fatty acid oxidation, thereby reducing intracellular lipid accumulation, and has the potential to inhibit disease progression by regulating lipid metabolism in NSCLC.

The invention belongs to the technical field of application of traditional Chinese medicine preparations, and discloses application of Jinshuiliujun decoction in preparation of a medicine for treating EGFR sensitive mutation non-small cell lung cancer, the medicine is used for being applied in combination with chemotherapy, a classic traditional Chinese medicine compound is combined with a modern chemotherapy regimen, and when a patient suffering from IIIb / IV-stage EGFR sensitive mutation is treated, the curative effect is good, and the curative effect is good. The pharmaceutical composition shows clear synergistic interaction and toxicity reduction effects, and the specific performance is as follows: the median progression-free lifetime of a patient is obviously prolonged; the traditional Chinese medicine syndromes such as cough and weakness are improved; the immunologic function is effectively regulated, and the CD4 + / CD8 + ratio is increased; the negative emotion score of the patient is reduced; the adverse reaction incidence rate of chemotherapy is not increased; a brand new traditional Chinese and western medicine combined treatment scheme is provided for the specific lung cancer subtype, and the curative effect and life quality are improved.

The invention belongs to the technical field of biomedicine, and particularly relates to application of SDAD1 as a target spot to preparation of a medicine for treating diffuse large B-cell lymphoma. The invention provides a biomarker SDAD1 gene or SDAD1 protein for auxiliary diagnosis of diffuse large B-cell lymphoma for the first time. The invention discovers that the progression-free lifetime and the total lifetime of patients with high SDAD1 expression are obviously shortened compared with those of patients with low expression for the first time, which prompts that the high expression of SDAD1 is related to poor prognosis of DLBCL patients. The LC1-DNAzyme drug capable of efficiently inhibiting SDAD1 gene expression is prepared, the effects of specifically recognizing DLBCL cells, inhibiting tumor cell proliferation and promoting tumor cell apoptosis can be achieved, and it is verified through a mouse tumor-bearing model that the drug can effectively treat lymphoma and is good in safety.

The invention discloses an application of ametinib or vomitinib, endol and oral vinorelbine in preparation of a medicine for treating a IV-stage non-small cell lung cancer patient carrying EGFR sensitive mutation, and belongs to the technical field of biological medicines. Wherein the bit progression-free lifetime (PFS) is up to 32.3 months. The composition is superior to third-generation EGFR-TKI single-drug treatment in the prior art and is also superior to most reported combined schemes. In addition, the PFS rates of 1 year, 2 years and 3 years are respectively as high as 91.7%, 66.7% and 41.7%, indicating that the scheme in the invention can provide lasting and stable disease control.

The invention discloses application of secretory LAMP1 as a non-small cell lung cancer immunotherapy curative effect and prognostic marker and an evaluation system, and relates to the technical field of biological medicine. According to the invention, sLAMP1 in serum is taken as a core biomarker, so that the curative effect and prognosis of ICB treatment of NSCLC patients can be effectively predicted. Meanwhile, a multi-dimensional prognosis evaluation system integrating sLAMP1 concentration, ECOG score, pathological subtype, gender, smoking state, age and other clinical pathological characteristics is constructed, and accurate prediction of one-year and three-year progression-free lifetime of the patient is realized. The system predicts that the AUC of PFS reaches up to 0.94 within 12 months, is easy to popularize in a standardized manner based on a mature ELISA platform, can assist clinicians in early screening of potential benefit crowds, identification of true and false progresses and timely adjustment of treatment strategies, can remarkably improve the precise whole-course management level of NSCLC immunotherapy, and has important clinical transformation value.

Disclosed is a method of treating a subject in need thereof, the method comprising: applying an alternating electric field to a target site of the subject in need thereof at a frequency over a period of time; and administering a Trop-2 specific therapeutic agent to the subject in need thereof. The disclosed methods may also enhance the efficacy of Trop-2 specific therapeutic agents, extend progression-free lifetime in cancer subjects, reduce tumor growth, and improve the killing effect of cancer cells.

Embodiments of the present disclosure relates to ivaltinostat combination therapy for treating pancreatic cancer in subjects having low levels of serological protein biomarkers with negative correlation to progression-free survival (PFS).

Methods for predicting overall survival (OS) and progression free survival (PFS) of subjects having cancer, based on the presence of certain structures associated with circulating cancer associated macrophage-like cells (CAMLs), including micronuclei (MN), extracellular vesicles (EVs), enlarged polynuclearization (EPN), internalized intact cells and large internal cellular debris, are provided.

The application belongs to the technical field of biological medicine, and particularly relates to RAB8A as a biomarker for predicting the curative effect and prognosis of immunotherapy of non-small cell lung cancer (NSCLC) patients and application thereof. Through independent discovery and verification queues, it is proved that high expression of RAB8A in tumor tissues is significantly related to longer progression-free survival of NSCLC patients after receiving immunotherapy, and the expression level has good prediction efficiency on the curative effect and prognosis of immunotherapy. Detection of RAB8A protein expression can be used as an effective auxiliary tool for guiding the clinical decision of NSCLC immunotherapy.

The invention belongs to the field of biological medicine, and particularly discloses application of a CDKN3 gene as an endometrial cancer (UCEC) biomarker and a treatment target. Bioinformatics analysis and clinical sample verification show that the CDKN3 is remarkably and highly expressed in UCEC tissues, and the expression level of the CDKN3 is positively correlated with tumor malignancy degrees (such as low differentiation, deep muscular infiltration and lymph node metastasis) and serum markers CA125 and CEA, and is an independent risk factor influencing the progression-free lifetime. Functional experiments show that the CDKN3 promotes proliferation and invasion of tumor cells by regulating the level of reactive oxygen species (ROS), and silencing of the CDKN3 can induce apoptosis and inhibit tumor growth. The invention also provides a prognosis prediction model (AUCgt; AUCgt) of CDKN3 combined with CA125 and CEA; the invention further discloses application of siRNA, shRNA, an antibody or a small-molecule inhibitor of the targeted CDKN3 to treatment of the UCEC, and a new strategy is provided for accurate diagnosis and targeted treatment of the UCEC.

The application provides an application of a CNOT9 expression inhibitor in preparation of a medicine for preventing, alleviating and / or treating liver cancer. It is found for the first time that the mRNA and protein expression levels of CNOT9 in hepatocellular carcinoma (HCC) tissues are significantly higher than those in paracancerous and normal liver tissues, and the high expression is closely related to the prognosis indexes such as the overall survival and progression-free survival of patients, thereby establishing the value of CNOT9 as a liver cancer diagnosis marker and a new treatment target. Based on this, the application provides an application of a CNOT9 inhibitor in preparation of a medicine for preventing, alleviating and / or treating liver cancer. By down-regulating the expression of CNOT9 through siRNA, the proliferation activity, clonogenicity, migration and invasion ability of liver cancer cells HLF can be effectively inhibited. The application further provides a medicine composition comprising the inhibitor, thereby providing a brand-new target and effective intervention strategy for liver cancer treatment, and having a great clinical development prospect and application value.

The invention provides application of an NAT9 expression inhibitor in preparation of a medicine for preventing, relieving and / or treating liver cancer. It is found for the first time that the mRNA and protein expression levels of NAT9 in hepatocellular carcinoma (HCC) tissue are obviously higher than those in para-carcinoma and normal liver tissue, and the high expression of NAT9 is closely related to prognosis indexes such as poor overall lifetime and progression-free lifetime of a patient, so that the value of NAT9 serving as a liver cancer diagnosis marker and a new treatment target is determined. On the basis, the invention provides the application of the NAT9 inhibitor in preparing the medicine for preventing, relieving and / or treating the liver cancer. NAT9 expression is down-regulated through siRNA, and the proliferation activity, the clone forming ability, the migration ability and the invasion ability of liver cancer cells HLF can be effectively inhibited. The invention further provides a pharmaceutical composition containing the inhibitor, a brand new target spot and an effective intervention strategy are provided for liver cancer treatment, and the pharmaceutical composition has great clinical development prospects and application value.

The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof (“an anti-PD-1 antibody monotherapy”). The methods of the invention can extend progression-free survival for over 12 months and / or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

The invention discloses a non-small cell lung cancer postoperative recurrence evaluation model construction method based on circulating blood tumor DNA. The non-small cell lung cancer postoperative recurrence evaluation model construction method comprises the following steps: S1, defining a detected sample with at least one credible mutation as ctDNA positive; s2, screening patients whose ctDNA single detection is negative within m months after operation, and obtaining clinical pathology information and perioperative ctDNA detection results of the patients; s3, integrating the clinical pathological information in the step S2 and the ctDNA detection result as an initial feature set, and screening a final feature set related to the progress-free lifetime by using LASSO regression and an XGBoost algorithm; and S4, constructing a prognosis evaluation model based on the final feature set, and verifying the prognosis evaluation model through the external queue data set to evaluate the efficiency of the model. According to the invention, the sensitivity of single detection of the ctDNA after the lung cancer operation is greatly improved, the ctDNA is closer to clinical requirements, and practical and effective positive influences are provided for treatment decisions.